Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

Everybody wants their hands on NVIDIA's GPUs, with the AI favorite continuing to ink fresh deals and collaborate with many ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when ...

The best stocks to invest in often are industry leaders in vast markets. These five stocks are likely to continue making ...

BP named a new board chair after activist shareholders pressured the company to move in a new direction. The London-based ...

Richmond was named Canada's Most Active Community in the national 2025 ParticipACTION Community Challenge, and has won ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to go somewhere in Virginia.

Here are nine new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...